Clinical trials in Roubaix – page 7

1 745 clinical trials in Roubaix, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Roubaix at a glance

1 745

clinical trials

Research sites1

Quick filters

1 745 trials in Roubaix

Open in trial search

Chronic myeloid leukaemia

Recruiting

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Bosutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Oesophageal squamous cell carcinoma

Recruiting

Ifinatamab deruxtecan in Patients With Advanced Esophageal Squamous Cell Carcinoma

InvestigationalNo placebo

Ifinatamab deruxtecan in Patients With Advanced Esophageal Squamous Cell Carcinoma

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ifinatamab Deruxtecan
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Anaemia+1

Recruiting

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Epoetin Alfa
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Acquired C1 inhibitor deficiency

Recruiting

Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema

Investigational

Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema

Investigational

France

Participants:18–64 years · 65+ years
Substances:Deucrictibant
Sponsor:Pharvaris Netherlands B.V.

Contact Research Centre

Gastric cancer+2

Recruiting

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Waldenstrom's macroglobulinaemia+2

Recruiting

A study to evaluate the effectiveness of epcoritamab in patients with Waldenström's macroglobulinemia that has returned or has not responded to previous treatments.

InvestigationalNo placebo

A study to evaluate the effectiveness of epcoritamab in patients with Waldenström's macroglobulinemia that has returned or has not responded to previous treatments.

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Clear cell renal cell carcinoma

Recruiting

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:AB521
Sponsor:Arcus Biosciences Inc.

Contact Research Centre

Non-small cell lung cancer stage IV+2

Recruiting

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Ischaemic stroke

Recruiting

Study on JX10 for Improving Outcomes in Patients with Acute Ischemic Stroke

Investigational

Study on JX10 for Improving Outcomes in Patients with Acute Ischemic Stroke

Investigational

France

Participants:18–64 years · 65+ years
Substances:JX10
Sponsor:Corxel Pharmaceuticals Co. Ltd.

Contact Research Centre

Malignant melanoma

Recruiting

Study on IMA203 for Patients with Previously Treated Unresectable or Metastatic Skin Melanoma

Registered drugNo placebo

Study on IMA203 for Patients with Previously Treated Unresectable or Metastatic Skin Melanoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Immatics US Inc.

Contact Research Centre

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Carboplatin
Sponsor:The University Of Birmingham

Contact Research Centre

Prostate cancer metastatic

Recruiting

Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability

InvestigationalNo placebo

Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Darolutamide
Sponsor:Unicancer

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Roubaix

What the registry says about research in the country

01 Hematologic Oncology

Research focusing on innovative treatments for Multiple Myeloma and various forms of leukemia, including comparative studies of novel therapeutic combinations and traditional approaches.

Multiple Myeloma therapies
Acute Myeloid Leukemia treatments
Myeloproliferative disorders

Studies evaluating treatment effectiveness in newly diagnosed patients and those with advanced disease stages.

02 Neurological Disorders

Innovative research exploring potential treatments for Alzheimer's disease, including studies on caffeine's effects on cognitive function in early-to-moderate stage patients.

Cognitive decline prevention
Novel therapeutic approaches
Disease progression monitoring

Focus on non-pharmacological interventions and their impact on disease progression.

03 Respiratory Medicine

Clinical investigations into severe asthma management and pulmonary infections, including studies on treatment optimization and novel therapeutic approaches.

Severe allergic asthma control
Mycobacterium avium complex treatment
Medication withdrawal studies

Evaluation of long-term treatment strategies and comparative medication studies.

04 Cardiovascular and Renal Studies

Research examining hypertension management in patients with chronic kidney disease, along with studies on thrombo-embolic complications prevention.

Blood pressure management
Kidney disease progression
Cardiovascular risk reduction

Focus on optimizing treatment strategies for complex cardiovascular conditions.

Back to France All countries